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background:  The PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES) has a novel metal and stent design 
intended to improve deliverability, comformability, and radial strength, whereas such features might have the trade-off of reducing 
longitudinal stent strength, which would account for the occurrence of longitudinal stent deformation (LSD) as reported previously. 
However, the incidence and clinical impact of LSD after PtCr-EES implantation in clinical practice have not been fully evaluated.
methods:  A total of 803 patients with 1050 lesions undergoing PtCr-EES implantation between March 2012 and August 2013 were 
analyzed. LSD was defined as the distortion or shortening and elongation of a stent in the longitudinal axis following successful stent 
deployment. We assessed the incidence of longitudinal stent deformation and cumulative incidence of major adverse cardiac events 
(MACE), defined as a composite of cardiac death, non-fatal myocardial infarction, definite stent thrombosis, and clinically driven target 
lesion revascularization within 1-year.
results:  Of 803 patients with 1050 lesions, we performed an intravascular ultrasound (IVUS) and post-dilatation in 752 patients (93.6%) 
with 992 lesions (94.5%) and in 408 patients (50.8%) with 538 lesions (51.2%). In the LSD group, IVUS and post-dilatation were performed 
in all patients. LSD was observed in 12 patients (1.5%) with 12 lesions (1.1%). The mechanism of LSD was due to the following reasons: 
compression by post-dilatation balloons (n=1, 8.3%), entrapped IVUS (n=8, 66.7%) and pull backed jailed guide wire (n=3, 25%). At 
1-year, the cumulative incidence of MACE, cardiac death, myocardial infarction, stent thrombosis and clinically driven target lesion 
revascularization were not significantly different between the LSD and non-LSD groups (9.1% vs. 2.8%, p=0.19; 0% vs. 0%, p=1.00; 0% vs. 
0.1%, p=0.92; 0% vs. 0.14%, p=0.88; 9.1% vs. 2.8%, p=0.19, respectively).
Conclusion:  LSD after PtCr-EES implantation occurs in 1.1% of lesions. However, LSD is not associated with MACE within 1-year.
